Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Oct;37(10):1008-1010.
doi: 10.1097/INF.0000000000001964.

Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children

Diane E T Bastiaans  1   2 , Sibyl P M Geelen  3 , Eline G Visser  4 , Michiel van der Flier  5 , Clementien L Vermont  4   6 , Angela P H Colbers  1 , Monique Roukens  1 , David M Burger  1 , Annemarie M C van Rossum  4 ; Dutch Paediatric HIV Study Group
Affiliations
Multicenter Study

Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children

Diane E T Bastiaans et al. Pediatr Infect Dis J. 2018 Oct.

Abstract

In this multicenter pharmacokinetic study in HIV-infected children (6-12 years of age), we validated the approved once-daily darunavir/ritonavir dosing recommendations. The geometric mean darunavir area under the plasma concentration-time curve was 63.1 h·mg/L, substantially lower than the mean value observed in adults. However, all trough levels were adequate, and short-term virologic outcome was good. These data support the use of the darunavir/ritonavir once-daily dosing recommendations.

PubMed Disclaimer